These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 7647999)

  • 41. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.
    MacArthur JM; Bishop JR; Stanford KI; Wang L; Bensadoun A; Witztum JL; Esko JD
    J Clin Invest; 2007 Jan; 117(1):153-64. PubMed ID: 17200715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lipolysis exposes unreactive endogenous apolipoprotein E-3 in human and rat plasma very low density lipoprotein.
    Sehayek E; Lewin-Velvert U; Chajek-Shaul T; Eisenberg S
    J Clin Invest; 1991 Aug; 88(2):553-60. PubMed ID: 1864965
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein.
    Beisiegel U; Weber W; Ihrke G; Herz J; Stanley KK
    Nature; 1989 Sep; 341(6238):162-4. PubMed ID: 2779654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: a major pathway at physiological particle concentrations.
    Al-Haideri M; Goldberg IJ; Galeano NF; Gleeson A; Vogel T; Gorecki M; Sturley SL; Deckelbaum RJ
    Biochemistry; 1997 Oct; 36(42):12766-72. PubMed ID: 9335533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels.
    Wang L; Shearer GC; Budamagunta MS; Voss JC; Molfino A; Kaysen GA
    Kidney Int; 2012 Nov; 82(9):990-9. PubMed ID: 22785171
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL.
    Murdoch SJ; Breckenridge WC
    Atherosclerosis; 1995 Dec; 118(2):193-212. PubMed ID: 8770314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modern management of hyperlipidemia.
    Grundy SM
    Compr Ther; 1984 Sep; 10(9):46-53. PubMed ID: 6091992
    [No Abstract]   [Full Text] [Related]  

  • 48. Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism.
    Havel RJ; Hamilton RL
    Hepatology; 1988; 8(6):1689-704. PubMed ID: 2847970
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lipoprotein metabolism.
    Beisiegel U
    Eur Heart J; 1998 Feb; 19 Suppl A():A20-3. PubMed ID: 9519338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
    Dergunov AD; Novoselov AV; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biol Chem; 2005 May; 386(5):441-52. PubMed ID: 15927888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction of apo E-containing lipoproteins with the LDL receptor-related protein LRP.
    Küchenhoff A; Harrach-Ruprecht B; Robenek H
    Am J Physiol; 1997 Feb; 272(2 Pt 1):C369-82. PubMed ID: 9124278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E. Accelerated clearance of lipoproteins containing apolipoprotein B.
    Shimano H; Yamada N; Katsuki M; Yamamoto K; Gotoda T; Harada K; Shimada M; Yazaki Y
    J Clin Invest; 1992 Nov; 90(5):2084-91. PubMed ID: 1430232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Familial type III hyperlipoproteinemia].
    Kataoka S; Egusa G
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():69-73. PubMed ID: 11347154
    [No Abstract]   [Full Text] [Related]  

  • 54. Delayed clearance of chylomicron remnants following vitamin-A-containing oral fat loads in broad-beta disease (type III hyperlipoproteinemia).
    Hazzard WR; Bierman EL
    Metabolism; 1976 Jul; 25(7):777-801. PubMed ID: 181657
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interactions of triglyceride-rich lipoproteins with receptors: modulation by thrombin.
    Gianturco SH; Bradley WA
    Semin Thromb Hemost; 1986 Oct; 12(4):277-9. PubMed ID: 3787267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein.
    Beisiegel U; Weber W; Bengtsson-Olivecrona G
    Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8342-6. PubMed ID: 1656440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
    J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Familial lipoprotein lipase deficiency: abnormal lipoproteins and defective metabolism of low density lipoproteins in cultured human skin fibroblasts.
    Kleinmann Y; Oschry Y; Berger GM; Eisenberg S
    Atherosclerosis; 1988 Jun; 71(2-3):197-204. PubMed ID: 3401291
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Lipoprotein receptors. Old acquaintances and newcomers].
    Ducobu J
    Rev Med Brux; 1997 Feb; 18(1):10-5. PubMed ID: 9132912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Studies on the binding and degradation of human very-low-density lipoproteins by human hepatoma cell line HepG2.
    Dashti N; Wolfbauer G
    Biochim Biophys Acta; 1986 Feb; 875(3):473-86. PubMed ID: 3004589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.